CN115969814A - 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法 - Google Patents

含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法 Download PDF

Info

Publication number
CN115969814A
CN115969814A CN202310039510.9A CN202310039510A CN115969814A CN 115969814 A CN115969814 A CN 115969814A CN 202310039510 A CN202310039510 A CN 202310039510A CN 115969814 A CN115969814 A CN 115969814A
Authority
CN
China
Prior art keywords
indirubin
solvent
dihydro
derivative
benzazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310039510.9A
Other languages
English (en)
Chinese (zh)
Inventor
吴斌
P·布歇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Satodam Corp
Original Assignee
Phosphorex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosphorex Inc filed Critical Phosphorex Inc
Publication of CN115969814A publication Critical patent/CN115969814A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202310039510.9A 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法 Pending CN115969814A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762478317P 2017-03-29 2017-03-29
US62/478,317 2017-03-29
PCT/US2018/025075 WO2018183631A1 (en) 2017-03-29 2018-03-29 Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
CN201880035839.5A CN110709066A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880035839.5A Division CN110709066A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Publications (1)

Publication Number Publication Date
CN115969814A true CN115969814A (zh) 2023-04-18

Family

ID=63676834

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310039510.9A Pending CN115969814A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法
CN201880035839.5A Pending CN110709066A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880035839.5A Pending CN110709066A (zh) 2017-03-29 2018-03-29 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法

Country Status (7)

Country Link
US (3) US20200016087A1 (https=)
EP (1) EP3600259A4 (https=)
JP (2) JP2020515598A (https=)
CN (2) CN115969814A (https=)
AU (1) AU2018244442A1 (https=)
CA (1) CA3058407A1 (https=)
WO (1) WO2018183631A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855423B1 (ko) * 2017-04-18 2018-05-09 주식회사 씨케이바이오텍 인디루빈 유도체를 유효성분으로 포함하는 약학 조성물
MX2021012548A (es) * 2019-04-17 2023-01-05 Azora Therapeutics Inc Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
US12303490B2 (en) 2019-11-04 2025-05-20 Ck Regeon Inc. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
CN115175673A (zh) * 2020-02-26 2022-10-11 上海科技大学 双硫仑在抗冠状病毒中的应用
WO2022229985A1 (en) * 2021-04-29 2022-11-03 Jawaharlal Nehru Centre For Advanced Scientific Research Soluble analogues of 6bio thereof and implementation thereof
CN118317948A (zh) 2021-10-08 2024-07-09 阿佐拉治疗股份有限公司 芳烃受体激动剂的衍生物
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550206A (zh) * 2013-10-23 2014-02-05 重庆市中药研究院 一种白藜芦醇靛玉红组合药物、缓释微囊剂及其应用
CN106029065A (zh) * 2013-12-20 2016-10-12 法斯瑞斯公司 靛玉红固体分散组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686988A1 (en) * 2003-10-28 2006-08-09 The Rockefeller University Indirubin-type compounds, compositions, and methods for their use
WO2012012616A1 (en) * 2010-07-21 2012-01-26 Patty-Fu Giles Photoactive vitamin nanoparticles for the treatment of chronic wounds
WO2012135813A1 (en) * 2011-03-31 2012-10-04 University Of Rochester Methods and compositions for mesenchymal stem cell proliferation
US9707186B2 (en) * 2012-02-21 2017-07-18 Amrita Vishwa Vidyapeetham Core-shell particle formulation for delivering multiple therapeutic agents
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
ES2685743T3 (es) * 2012-02-29 2018-10-11 Merck Patent Gmbh Procedimiento para la fabricación de nanopartículas cargadas con principio activo
EP2863897B1 (en) * 2012-06-21 2019-06-19 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents
EP2878312A1 (en) * 2013-12-02 2015-06-03 Albert-Ludwigs-Universität Freiburg Reversible PEGylation of nanocarriers
WO2016197262A1 (en) * 2015-06-12 2016-12-15 Bayer Pharma Aktiengesellschaft Process for the preparation of porous microparticles
JP2018523702A (ja) * 2015-08-17 2018-08-23 フォスフォレックス，インコーポレイテッド 分解性ポリマーの極小ナノ粒子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550206A (zh) * 2013-10-23 2014-02-05 重庆市中药研究院 一种白藜芦醇靛玉红组合药物、缓释微囊剂及其应用
CN106029065A (zh) * 2013-12-20 2016-10-12 法斯瑞斯公司 靛玉红固体分散组合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
RUI FANG ET AL: "Sustained co-delivery of BIO and IGF-I by a novel hybrid hydrogel system to stimulate endogenous cardiac repair in myocardial infarcted rat hearts", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 10, 31 December 2015 (2015-12-31), pages 4691 - 4703, XP055738411, DOI: 10.2147/IJN.S81451 *
YANWANG ET AL: "Synthesis of Biodegradable Poly(butylenes terephthalate)/poly(ethylene glycol) (PBT/PEG) Multiblock Copolymers and Preparation of Indirubin Loaded Microspheres", POLYMER BULLETIN, vol. 53, 30 December 2004 (2004-12-30), pages 147 - 154 *
梅兴国: "微载体药物递送系统", 30 November 2009, 华中科学技术出版社, pages: 89 - 97 *
郑俊民: "药用高分子材料学", 31 January 2009, 中国医药出版社, pages: 175 *
马瑞: "生物学前沿技术在医学研究中的应用", 30 September 2007, 复旦大学出版社, pages: 341 - 347 *
高焕民等: "纳米医学", 31 May 2006, 军事医学科学出版社, pages: 103 - 105 *

Also Published As

Publication number Publication date
CN110709066A (zh) 2020-01-17
WO2018183631A1 (en) 2018-10-04
JP2020515598A (ja) 2020-05-28
CA3058407A1 (en) 2018-10-04
US20230100193A1 (en) 2023-03-30
US20200016087A1 (en) 2020-01-16
WO2018183631A8 (en) 2019-08-15
EP3600259A4 (en) 2020-11-25
AU2018244442A1 (en) 2019-10-24
US20200383931A1 (en) 2020-12-10
EP3600259A1 (en) 2020-02-05
JP2023040147A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
CN115969814A (zh) 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法
US7906479B2 (en) Sterile suspensions of slightly soluble basic peptide complexes and pharmaceutical formulations containing them
US9504652B2 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
KR102168263B1 (ko) 주사 제제
WO2016155655A1 (zh) Parp抑制剂固体药物剂型及其应用
JP2022538909A (ja) Ｃａｒ－ｔ細胞療法のための脂質－フルオレセイン結合体の設計および効率的合成の方法
BRPI0708343A2 (pt) formulações de carvedilol nanoparticuladas
CN106061261A (zh) 治疗化合物的结晶形式及其用途
EP3843705B1 (en) Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents
CN100518831C (zh) 固体纳米药物及其制备方法
EP3915538A1 (en) Injection composition containing fab i inhibitor, and preparation method therefor
EP3682894A1 (en) Cell autophagy inhibitor and preparation method therefor and application thereof
JP2018199685A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP5288791B2 (ja) 難水溶性物質含有微細化組成物
CN108601793B (zh) 使用5′-腺苷二磷酸核糖(adpr)的方法
JP2013151574A (ja) チューブリンインヒビターであるインジブリン（Ｉｎｄｉｂｕｌｉｎ）の改良された薬物動態学を有する、経口投与のための薬剤組成物、及びその製造法
CN117545479A (zh) Pi3k抑制剂、纳米制剂及其用途
CN110384803B (zh) 一种大环主体分子作为药物增溶剂的应用
JP2009504615A (ja) ７−（ｔ−ブトキシ）イミノメチルカンプトテシンのための製剤
CN118766866A (zh) 改善治疗剂的溶解度和生物利用度的方法
CN116370409A (zh) 司替戊醇纳米混悬液、纳米胶束及其制备方法与应用
HK1132903A (en) Nanoparticulate carvedilol formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230918

Address after: Massachusetts

Applicant after: Satodam Corp.

Address before: Massachusetts

Applicant before: PHOSPHOREX, Inc.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230418

WD01 Invention patent application deemed withdrawn after publication